Navigation Links
BioMed Realty Announces 80,500 Square Foot Lease Expansion For Regeneron Pharmaceuticals
Date:10/26/2012

SAN DIEGO, Oct. 26, 2012 /PRNewswire/ -- BioMed Realty Trust, Inc. (NYSE: BMR) today announced that Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has leased an additional 80,500 square feet of space at The Landmark at Eastview campus in Tarrytown, New York comprised of approximately 46,000 square feet of space in the 777 Building and approximately 34,500 square feet of space in the 765 Building.

Named as the world's top biopharmaceutical employer in a recent Science magazine survey, as well as one of the 20 best places to work in the U.S. science industry by The Scientist magazine, Regeneron will use the new research and development laboratories for its research into treatments for ophthalmology, cancer, inflammation, hypercholesterolemia, and other conditions.  Regeneron markets three products in the United States: EYLEA® (aflibercept) Injection, ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST® (rilonacept) Injection for Subcutaneous Use. ZALTRAP is co-commercialized with Sanofi.

According to Alan D. Gold, Chairman and Chief Executive Officer of BioMed Realty, "Our singular focus is to create optimal environments that support transformational research and groundbreaking science. Our eight-year relationship with Regeneron, one of the truly inspiring stories in the life science industry, exemplifies this commitment. We salute our friends at Regeneron on their successful launch of EYLEA, the recent launch of ZALTRAP, and the groundbreaking research being performed every day at The Landmark. With their latest expansion, we look forward to supporting their success for many years to come."

The Landmark at Eastview is one of the largest privately-owned, multi-tenant science parks in New York State. The campus consists of eight buildings and over 1.1 million rentable square feet of research and development facilities and high-tech office space.

About BioMed Realty Trust

BioMed Realty delivers optimal real estate solutions for biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed Realty owns or has interests in properties comprising approximately 13.1 million rentable square feet. The company's properties are located predominantly in the major U.S. life science markets of Boston, San Francisco, San Diego, Maryland, New York/New Jersey, Pennsylvania and Seattle, which have well-established reputations as centers for scientific research.  Additional information is available at www.biomedrealty.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, without limitation: general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants' financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the company'target markets; risks associated with the availability and terms of financing, the use of debt to fund acquisitions, developments and other investments, and the ability to refinance indebtedness as it comes due; failure to maintain the company's investment grade credit ratings with the ratings agencies; failure to manage effectively the company's growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully; reductions in asset valuations and related impairment charges; risks and uncertainties affecting property development and construction; risks associated with downturns in foreign, domestic and local economies, changes in interest rates and foreign currency exchange rates, and volatility in the securities markets; ownership of properties outside of the United States that subject the company to different and potentially greater risks than those associated with the company's domestic operations; risks associated with the company's investments in loans, including borrower defaults and potential principal losses; potential liability for uninsured losses and environmental contamination; risks associated with the company's potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company's dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMed Realty
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Medical Device Developers - Network at BIOMEDevice Boston Next Week
2. Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
3. Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion
4. Fluke Biomedical launches speedy new ProSim™ SPOT Light SpO2 Functional Tester
5. Oramed Pharmaceuticals to Present at the 11th National Life Science & Technology Week ILSI-BIOMED Conference; Tel Aviv, Israel, 2012
6. Fluke Biomedical device first to achieve environmentally-friendly label
7. NexGen Biomedical, Inc. Provides New Insights Into Jett Travoltas Seizure Related Death
8. 81,200 Square Foot Lease Extension In San Diego Through 2018 Signed By Vertex Pharmaceuticals And BioMed Realty
9. The Biomedical Device Industry in America: Challenges at Home and Abroad
10. BioMed Diagnostics Microbiology Diagnostic Devices Now Available Worldwide Through Distribution Agreement With VWR International, LLC
11. BioMed Realty Trust Converts $156.4 Million Of Its Senior Unsecured Term Loan To 100 Million Pounds Sterling
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global ... solutions, today announced that it is teaming up with ... Limited to lower diabetes healthcare costs in ... which is available throughout all provinces and territories in ... eligible for additional savings when shopping for Dario supplies ...
(Date:5/3/2017)... , May 3, 2017 A ... any hospital or healthcare facility. Commonly referred to ... is equipped with diagnostic imaging technology to give ... the heart. In these spaces, a team of ... balloon angioplasty, percutaneous coronary intervention, congenital heart defect ...
(Date:5/3/2017)...  West Pharmaceutical Services, Inc. (NYSE: WST), a ... administration, announced today that Fran DeGrazio , ... Diane Paskiet , Director, Scientific Affairs, are ... West,s expertise in the areas of safety and ... commentary on updated industry guidance. ...
Breaking Medicine Technology:
(Date:5/24/2017)... Ca (PRWEB) , ... May 24, 2017 , ... ... effects and background. Understanind and choosing the most appropriate instruments for research and ... critical in research finding. This webinar will focus on innovations in stereo microscopy ...
(Date:5/24/2017)... Cincinnati, OH (PRWEB) , ... May 24, 2017 , ... ... discreet and comfortable ClearCorrect orthodontics, with or without a referral. Dr. Kejriwal ... is why she offers convenient, clear braces in Cincinnati, OH. Patients no longer need ...
(Date:5/24/2017)... Birmingham, Clarkston, Lake Orion, Michigan (PRWEB) , ... ... ... Endometriosis is a disease affecting the female reproductive tract in which ... itself on the pelvic structures causing inflammation and pain. Patients experiencing painful ...
(Date:5/24/2017)... ... 24, 2017 , ... Rob Lowe is a sought after actor, and also ... brings the public important topics from all aspects of life, and a new segment ... surrounding feet and ankles. , Podiatry is essential to people’s overall well-being, and if ...
(Date:5/23/2017)... ... May 23, 2017 , ... MDLand International ... company, announced today that its iClinic V12.2 solution has achieved approval from National ... recently introduced PCMH 2017 standards which emphasize team-based care with a significant focus ...
Breaking Medicine News(10 mins):